Gilead Sciences | Netto Inntekt



Net Income Endring Dato
AbbVie USD -22000000 1.58B 2024-12
Agios Pharmaceuticals USD -96523000 1.04B 2024-12
ALKERMES USD 367.07M 274.69M 2024-12
Alnylam Pharmaceuticals USD -83763000 27.81M 2024-12
Amgen USD 627M 2.2B 2024-12
Biogen USD 266.7M 121.8M 2024-12
BioMarin Pharmaceutical USD 124.94M 18.86M 2024-12
Bristol-Myers Squibb USD 72M 1.14B 2024-12
Eli Lilly USD 4.41B 3.44B 2024-12
Gilead Sciences USD 1.78B 529M 2024-12
GlaxoSmithKline GBP 414M 472M 2024-12
Glaxosmithkline GBP 414M 472M 2024-12
Incyte USD 201.21M 94.76M 2024-12
J&J USD 3.43B 737M 2024-12
Merck USD 3.74B 586M 2024-12
Moderna USD -1120000000 1.13B 2024-12
Neurocrine Biosciences USD 103.1M 26.7M 2024-12
Novartis USD 2.82B 371M 2024-12
Pfizer USD 410M 4.06B 2024-12
PTC Therapeutics USD -65886000 40.77M 2024-12
Regeneron Pharmaceuticals USD 917.7M 422.9M 2024-12
Sanofi EUR 2.82B 1.7B 2024-09
Sarepta Therapeutics USD 159.05M 125.44M 2024-12
United Therapeutics USD 301.3M 7.8M 2024-12
Vertex Pharmaceuticals USD 913M 132.4M 2024-12



Gilead Sciences Netto Inntekt - Gjeldende verdier, historiske data, prognoser, statistikk, diagrammer og økonomiske kalender - Mar 2025.